SG11201403749VA - Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists - Google Patents

Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Info

Publication number
SG11201403749VA
SG11201403749VA SG11201403749VA SG11201403749VA SG11201403749VA SG 11201403749V A SG11201403749V A SG 11201403749VA SG 11201403749V A SG11201403749V A SG 11201403749VA SG 11201403749V A SG11201403749V A SG 11201403749VA SG 11201403749V A SG11201403749V A SG 11201403749VA
Authority
SG
Singapore
Prior art keywords
gonadotropin
receptor antagonists
hormone receptor
releasing hormone
spiroindoline derivatives
Prior art date
Application number
SG11201403749VA
Other languages
English (en)
Inventor
Olaf Panknin
Stefan BÄURLE
Sven Ring
Wolfgang Schwede
Wilhelm Bone
Katrin Nowak-Reppel
Eckhard Bender
Reinhard Nubbemeyer
Mark Jean Gnoth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201403749V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG11201403749VA publication Critical patent/SG11201403749VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201403749VA 2012-01-16 2013-01-15 Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists SG11201403749VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12151291 2012-01-16
PCT/EP2013/050676 WO2013107743A1 (en) 2012-01-16 2013-01-15 Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Publications (1)

Publication Number Publication Date
SG11201403749VA true SG11201403749VA (en) 2014-07-30

Family

ID=47559493

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403749VA SG11201403749VA (en) 2012-01-16 2013-01-15 Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Country Status (25)

Country Link
US (1) US20140357655A1 (pt)
EP (1) EP2804867A1 (pt)
JP (1) JP2015503607A (pt)
KR (1) KR20140112075A (pt)
CN (1) CN104169287A (pt)
AP (1) AP2014007738A0 (pt)
AU (1) AU2013211091A1 (pt)
BR (1) BR112014017483A8 (pt)
CA (1) CA2860986A1 (pt)
CL (1) CL2014001871A1 (pt)
CO (1) CO7010832A2 (pt)
CR (1) CR20140343A (pt)
CU (1) CU20140088A7 (pt)
DO (1) DOP2014000167A (pt)
EA (1) EA201491344A1 (pt)
GT (1) GT201400153A (pt)
HK (1) HK1199878A1 (pt)
IL (1) IL233485A0 (pt)
MA (1) MA35867B1 (pt)
MX (1) MX2014008630A (pt)
PE (1) PE20141699A1 (pt)
PH (1) PH12014501616A1 (pt)
SG (1) SG11201403749VA (pt)
TN (1) TN2014000306A1 (pt)
WO (1) WO2013107743A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095785A1 (es) * 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
WO2015007606A1 (en) * 2013-07-15 2015-01-22 Bayer Pharma Aktiengesellschaft Spiroindoline derivatives and pharmaceutical compositions thereof
WO2015082374A1 (en) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Spiroindoline-thiopyran-imine-oxide derivatives as gonadotropin-releasing hormone receptor antagonists and pharmaceutical compositions thereof
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
WO2015091315A1 (en) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Spiro[indolin-3,4'-piperidine] derivatives as gnrh receptor antagonists
EP3339846B1 (en) * 2016-12-22 2020-12-09 Malvern Panalytical B.V. Method of measuring properties of a thin film stack
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CN107840851A (zh) * 2017-12-21 2018-03-27 扬州大学 吲哚螺吡咯嗪化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds

Also Published As

Publication number Publication date
AU2013211091A1 (en) 2014-08-07
KR20140112075A (ko) 2014-09-22
PH12014501616A1 (en) 2014-10-13
TN2014000306A1 (en) 2015-12-21
CO7010832A2 (es) 2014-07-31
AP2014007738A0 (en) 2014-07-31
CR20140343A (es) 2014-09-08
BR112014017483A8 (pt) 2017-07-04
CN104169287A (zh) 2014-11-26
IL233485A0 (en) 2014-08-31
BR112014017483A2 (pt) 2017-06-13
GT201400153A (es) 2015-05-22
HK1199878A1 (en) 2015-07-24
US20140357655A1 (en) 2014-12-04
JP2015503607A (ja) 2015-02-02
MA35867B1 (fr) 2014-12-01
CU20140088A7 (es) 2014-12-26
WO2013107743A1 (en) 2013-07-25
EP2804867A1 (en) 2014-11-26
EA201491344A1 (ru) 2015-04-30
CL2014001871A1 (es) 2014-11-03
DOP2014000167A (es) 2014-08-31
CA2860986A1 (en) 2013-07-25
MX2014008630A (es) 2014-08-29
PE20141699A1 (es) 2014-11-29

Similar Documents

Publication Publication Date Title
HK1203191A1 (en) P2x4 receptor antagonist p2x4
HK1252279A1 (zh) 5- ht3受體拮抗劑
HK1199878A1 (en) Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists
HUE039607T2 (hu) Progeszteron antagonisták
SI2833864T1 (sl) Farmacevtske formulacije, ki obsegajo antagoniste CCR3
IL244356A0 (en) Formulations for cgrp receptor antagonists
EP2874621A4 (en) Mineralocorticoid receptor antagonists
HK1216101A1 (zh) 用作促性腺激素釋放激素受體拮抗劑的螺二氫吲哚衍生物
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
GB201213699D0 (en) Receptor antagonists II
GB201213698D0 (en) Receptor antagonists II